GLYCART biotechnology AG

GLYCART biotechnology AG is active in the research and development of new potent antibody-based products for the treatment of unmet clinical needs such as cancer. GLYCART uses its proprietary set of technologies to endow therapeutic antibodies with competitive advantages. The Company has developed glycoengineering technology (GlycoMAb®) to boost a natural mechanism of action of therapeutic antibodies developed to mediate target cell killing. In addition to GlycoMAb®, GLYCART has developed additional proprietary technologies covering all key elements of the monoclonal antibody value chain in order to streamline its product development efforts while minimizing potential royalty stacking.

Contact Details: Wagistrasse 18 Schlieren Zurich CH-8952 Switzerland Tel: 41 44 755 6161 Fax: 41 44 755 6160 Email: info@glycart.com WWW: www.glycart.com/

Recent Publications by GLYCART biotechnology AG:
Modulation of therapeutic antibody effector functions by glycosylation engineering: influence of Golgi enzyme localization domain and co-expression of heterologous beta1, 4-N-acetylglucosaminyltransferase III and Golgi alpha-mannosidase II. The effector functions elicited by IgG antibodies strongly depend on the...	25th May, 2006	GLYCART biotechnology AG, Wagistrasse 18, CH-8952 Schlieren, Switzerland.	Biotechnol Bioeng. 2006 Apr 5;93(5):851-61. DOI Direct Link
The carbohydrate at FcgammaRIIIa Asn-162. An element required for high affinity binding to non-fucosylated IgG glycoforms. FcgammaRIIIa plays a prominent role in the elimination of tumor cells by...	5th May, 2006	GLYCART Biotechnology AG (Roche Group), Wagistrasse 18, CH-8952 Schlieren,	J Biol Chem. 2006 Feb 24;281(8):5032-6. Epub 2005 Dec 5. DOI Direct Link

BioNews Results for GLYCART biotechnology AG:
N.J. index reaches a yearly high	Asbury Park Press:  Nov 22 2009 12:49PM Matching: biotechnolog ag
The test to speed up war on cancer	Sydney Morning Herald:  Nov 22 2009 7:45PM Matching: biotechnolog ag
Encorium Group, Inc. Appoints Sari Laitinen to Board of Directors	Pharma Live:  Nov 22 2009 3:01PM Matching: biotechnolog ag
New campaign focuses on using makeup to minimize effects of certain cancer treatments	SGV Tribune:  Nov 21 2009 7:55PM Matching: biotechnolog ag
FDA approves sNDA for pediatric autism drug ABILIFY	News-Medical.Net:  Nov 21 2009 4:57AM Matching: biotechnolog ag
Promote your company here: BioNewsCast - Press Release Distribution	→View more GLYCART biotechnology AG news.

GLYCART biotechnology AG Patents:
US Patent No.	Title
7517670	Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
6602684	Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 576 times since April 2007, the link to the organisation's website has been followed 85 times

Recent Search Terms used to find this page: GlycArt patent | patent glycart | glycart address list | glycart biotechnology | glycart | glycart | glycomab review | glycart | glycart | glycart | .

Search for more companies in Schlieren

Search for more companies in Zurich

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for GLYCART biotechnology AG